From frontier research
to real decisions.
Intangia ingests all the important scientific, clinical, patent, company, deal, and investment data in biopharma, then detects and scores emerging opportunities at the target/indication/modality level so R&D and strategy teams can decide what to pursue, deprioritise, or kill, at a scale no human team can match
From frontier research
to real decisions.
Intangia ingests all the important scientific, clinical, patent, company, deal, and investment data in biopharma, then detects and scores emerging opportunities at the target/indication/modality level so R&D and strategy teams can decide what to pursue, deprioritise, or kill, at a scale no human team can match
From frontier research
to real decisions.
Intangia ingests all the important scientific, clinical, patent, company, deal, and investment data in biopharma, then detects and scores emerging opportunities at the target/indication/modality level so R&D and strategy teams can decide what to pursue, deprioritise, or kill, at a scale no human team can match
Success
“Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP, R&D Strategy, Mid-Cap Biotech
Success
“Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP, R&D Strategy, Mid-Cap Biotech
Success
“Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP, R&D Strategy, Mid-Cap Biotech
Problem
Most R&D failures are strategic
not scientific.
Failures start with the wrong decisions
Drug programs rarely fail because biology was unknowable. They fail because decisions lacked synthesis. Wrong targets, indications, timing, or competitive context.
Decisions lack full synthesis
Teams face fragmented evidence from papers, patents, trials, and internal work. Signals often emerge only after capital and resources are already committed.
Search retrieves data, not decisions
Search and dashboards surface what already exists. They do not support decision making under uncertainty, when teams must commit before consensus forms.
Problem
Most R&D failures are strategic
not scientific.
Failures start with the wrong decisions
Drug programs rarely fail because biology was unknowable. They fail because decisions lacked synthesis. Wrong targets, indications, timing, or competitive context.
Decisions lack full synthesis
Teams face fragmented evidence from papers, patents, trials, and internal work. Signals often emerge only after capital and resources are already committed.
Search retrieves data, not decisions
Search and dashboards surface what already exists. They do not support decision making under uncertainty, when teams must commit before consensus forms.
Problem
Most R&D failures are strategic
not scientific.
Failures start with the wrong decisions
Drug programs rarely fail because biology was unknowable. They fail because decisions lacked synthesis. Wrong targets, indications, timing, or competitive context.
Decisions lack full synthesis
Teams face fragmented evidence from papers, patents, trials, and internal work. Signals often emerge only after capital and resources are already committed.
Search retrieves data, not decisions
Search and dashboards surface what already exists. They do not support decision making under uncertainty, when teams must commit before consensus forms.
Our solution
The reasoning layer
that turns signals into actions
Unify evidence
Continuously ingests and organizes biomedical evidence across sources, normalizing signals so teams see the full landscape, not isolated findings.
Detect momentum
Formalize decisions
From Research to Commercial
Our solution
The reasoning layer
that turns signals into actions
Unify evidence
Continuously ingests and organizes biomedical evidence across sources, normalizing signals so teams see the full landscape, not isolated findings.
Detect momentum
Formalize decisions
From Research to Commercial
Our solution
The reasoning layer
that turns signals into actions
Unify evidence
Continuously ingests and organizes biomedical evidence across sources, normalizing signals so teams see the full landscape, not isolated findings.
Detect momentum
Formalize decisions
From Research to Commercial
Benefits
R&D capital allocation
without guesswork.
Make better R&D and partnering decisions by integrating translational, competitive, and IP evidence all in one place.
Faster Decisions
Move from signal to conviction without fragmented analysis or manual stitching.
Lower Strategic Risk
Reduce exposure to narrative-driven bets with evidence-linked decision trails.
Early Momentum Insight
See emerging targets, mechanisms and indications before they become consensus.
Governance-Ready Output
Produce traceable decision artifacts that investment committees and leadership can stand behind.
Benefits
R&D capital allocation
without guesswork.
Make better R&D and partnering decisions by integrating translational, competitive, and IP evidence all in one place.
Faster Decisions
Move from signal to conviction without fragmented analysis or manual stitching.
Lower Strategic Risk
Reduce exposure to narrative-driven bets with evidence-linked decision trails.
Early Momentum Insight
See emerging targets, mechanisms and indications before they become consensus.
Governance-Ready Output
Produce traceable decision artifacts that investment committees and leadership can stand behind.
Benefits
R&D capital allocation
without guesswork.
Make better R&D and partnering decisions by integrating translational, competitive, and IP evidence all in one place.
Faster Decisions
Move from signal to conviction without fragmented analysis or manual stitching.
Lower Strategic Risk
Reduce exposure to narrative-driven bets with evidence-linked decision trails.
Early Momentum Insight
See emerging targets, mechanisms and indications before they become consensus.
Governance-Ready Output
Produce traceable decision artifacts that investment committees and leadership can stand behind.
Use Cases
Where evidence turns
into defensible decisions
Drug hunting
Prioritising early targets based on translational momentum.
Comparing mechanisms before committing platform resources.
Asset repurposing
Identifying indications where an existing asset shows emerging traction.
Building evidence to support internal repurposing decisions.
Indication expansion
Identify adjacent indications where translational momentum is emerging ahead of consensus.
Support expansion decisions with evidence-linked rationale for internal and board review.
Portfolio prioritisation
Compare programs using a consistent, auditable evidence framework.
Allocate capital toward durable momentum rather than narrative-driven bets.
Use Cases
Where evidence turns
into defensible decisions
Drug hunting
Prioritising early targets based on translational momentum.
Comparing mechanisms before committing platform resources.
Asset repurposing
Identifying indications where an existing asset shows emerging traction.
Building evidence to support internal repurposing decisions.
Indication expansion
Identify adjacent indications where translational momentum is emerging ahead of consensus.
Support expansion decisions with evidence-linked rationale for internal and board review.
Portfolio prioritisation
Compare programs using a consistent, auditable evidence framework.
Allocate capital toward durable momentum rather than narrative-driven bets.
Use Cases
Where evidence turns
into defensible decisions
Drug hunting
Prioritising early targets based on translational momentum.
Comparing mechanisms before committing platform resources.
Asset repurposing
Identifying indications where an existing asset shows emerging traction.
Building evidence to support internal repurposing decisions.
Indication expansion
Identify adjacent indications where translational momentum is emerging ahead of consensus.
Support expansion decisions with evidence-linked rationale for internal and board review.
Portfolio prioritisation
Compare programs using a consistent, auditable evidence framework.
Allocate capital toward durable momentum rather than narrative-driven bets.
Built for
Built for
Built for
Biotech Companies
For ambitious biotechs expanding scientific and clinical scope. Capital is available; the constraint is deciding which expansion bets merit backing.
Biopharma & Pharma
For larger organisations allocating capital across many competing portfolios, disease areas, and platforms. Governance requires repeatable, auditable decision processes.
Business Development Teams
For teams licensing, partnering, or positioning assets in crowded and competitive landscapes. The challenge is separating durable momentum from transient hype.
Life Sciences Investors
For venture, growth, crossover, and public market investors seeking an edge ahead of pricing and consensus.
Clients
Trusted by teams
making smart, mission-critical decisions.
Clients
Trusted by teams
making smart, mission-critical decisions.
Clients
Trusted by teams
making smart, mission-critical decisions.
Results
Results
Results
Real impact.
In their own words.
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“We backed Intangia after the platform flagged a major acquisition 18 months before it closed. That early signal detection is exactly what pharma BD and R&D teams need, and why we’re excited to keep supporting the team as they scale.”
Partner
F-Prime
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech